These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1301361)

  • 41. Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers.
    Robbins DK; Hutcheson SJ; Miller TD; Green VI; Bhargava VO; Weir SJ
    Biopharm Drug Dispos; 1997 May; 18(4):325-34. PubMed ID: 9158880
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
    Martin DE; Blum R; Doto J; Galbraith H; Ballow C
    Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical pharmacokinetics of nefazodone.
    Greene DS; Barbhaiya RH
    Clin Pharmacokinet; 1997 Oct; 33(4):260-75. PubMed ID: 9342502
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans.
    Nakada N; Kawamura A; Kamimura H; Sato K; Kazuki Y; Kakuni M; Ohbuchi M; Kato K; Tateno C; Oshimura M; Usui T
    Biopharm Drug Dispos; 2016 Jan; 37(1):3-14. PubMed ID: 26352195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose-dependent pharmacokinetics and brain penetration of rufinamide following intravenous and oral administration to rats.
    Gáll Z; Vancea S; Szilágyi T; Gáll O; Kolcsár M
    Eur J Pharm Sci; 2015 Feb; 68():106-13. PubMed ID: 25530452
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study.
    Khan AY; Preskorn SH; Horst WD
    J Pak Med Assoc; 2007 May; 57(5):230-5. PubMed ID: 17571477
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses.
    Moore SA; Muñana KR; Papich MG; Nettifee-Osborne J
    Am J Vet Res; 2010 Mar; 71(3):337-41. PubMed ID: 20187836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
    Vollmer T; Blight AR; Henney HR
    Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
    Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
    J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil.
    Zhou XJ; Fielman BA; Lloyd DM; Chao GC; Brown NA
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2309-15. PubMed ID: 16801406
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation.
    Abernethy DR; Barbey JT; Franc J; Brown KS; Feirrera I; Ford N; Salazar DE
    Clin Pharmacol Ther; 2001 Mar; 69(3):96-103. PubMed ID: 11240972
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers.
    Areberg J; Søgaard B; Højer AM
    Basic Clin Pharmacol Toxicol; 2012 Sep; 111(3):198-205. PubMed ID: 22448783
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.
    Farré M; Roset PN; Llorente M; Márquez M; Albet C; Pérez JA; Herrero E; Ortíz JA
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):343-50. PubMed ID: 9379783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers.
    Da Ros L; Squassante L; Milleri S
    Clin Pharmacokinet; 2003; 42(1):99-106. PubMed ID: 12489980
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans.
    Vachharajani NN; Shyu WC; Greene DS; Barbhaiya RH
    Biopharm Drug Dispos; 1997 Apr; 18(3):191-202. PubMed ID: 9113342
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The pharmacokinetics of maropitant citrate dosed orally to dogs at 2 mg/kg and 8 mg/kg once daily for 14 days consecutive days.
    Lesman SP; Boucher JF; Grover GS; Cox SR; Bidgood TL
    J Vet Pharmacol Ther; 2013 Oct; 36(5):462-70. PubMed ID: 23167698
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of eltoprazine in the dog.
    Lammers R; van Harten J
    Drug Metabol Drug Interact; 1990; 8(1-2):141-8. PubMed ID: 2091887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Determination of nefazodone and its metabolites in plasma by high-performance liquid chromatography with coulometric detection.
    Franklin M
    J Pharm Biomed Anal; 1993; 11(11-12):1109-13. PubMed ID: 8123721
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
    Tran JQ; Othman AA; Mikulskis A; Wolstencroft P; Elkins J
    Clin Pharmacol; 2016; 8():9-13. PubMed ID: 26929672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.